Source: Guideline 2015
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Raghu, G., Rochwerg, B., Zhang, Y., et al.. Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks. Guideline 2015

Member's Comments

No comment yet.

Related content which might interest you: Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 What can we learn from Idiopathic Pulmonary Fibrosis Registries? Source: International Congress 2018 – The world of idiopathic pulmonary fibrosis (IPF): global registries Year: 2018 Bacterial Contamination of Home Nebulizers in Children with Cystic Fibrosis and Clinical Implication on the Number of Pulmonary Exacerbations Source: International Congress 2019 – Infection and inflammation in cystic fibrosis Year: 2019 Potential benefits of Nordic Walking for Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline Source: Guideline 2018 Year: 2018 Is Virtual Autonomous Physiotherapist Tele-rehabilitation Program feasible in Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – Muscle, exercise capacity and symptoms of chronic lung disease: a physio update Year: 2020 An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management Source: Guideline 2011 Year: 2011 Breath Biomarkers in Idiopathic Pulmonary Fibrosis: A Systematic Review Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018